← Browse by Condition

Medical Condition

non hodgkin lymphoma

Total Trials

17

Recruiting Now

17

Trial Phases

Phase 1, Phase 1, Phase 2, Phase 2

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — non hodgkin lymphoma Clinical Trials

How many clinical trials are currently recruiting for non hodgkin lymphoma?

ClinicalMetric currently tracks 17 actively recruiting clinical trials for non hodgkin lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 17. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for non hodgkin lymphoma?

non hodgkin lymphoma research spans Phase 1 (9 trials), Phase 2 (6 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a non hodgkin lymphoma clinical trial?

Eligibility criteria for non hodgkin lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

9

Phase 2

6

Top Sponsors

University of Colorado, Denver 2 trials

University of Wisconsin, Madison 1 trial

BeOne Medicines 1 trial

Marker Therapeutics, Inc. 1 trial

Estrella Biopharma, Inc. 1 trial

Recruiting Clinical Trials

Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families

University of Colorado, Denver

NCT02508038 Phase 1

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

University of Wisconsin, Madis...

NCT05006716 Phase 1, Phase 2

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

United States, Austr...

BeOne Medicines

NCT05798897 Phase 1

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

Marker Therapeutics, Inc.

NCT06343311 Phase 1, Phase 2

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Estrella Biopharma, Inc.

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

United States, Germa...

Bristol-Myers Squibb

NCT03125642 Phase 2

Auto Stem Cell Transplant for Lymphoma Patients

Masonic Cancer Center, Univers...

NCT07284927 Phase 1

Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies

PersonGen BioTherapeutics (Suz...

NCT05544019 Phase 1

Study of SGR-1505 in Mature B-Cell Neoplasms

United States, Franc...

Schrödinger, Inc.

New Approaches for the Diagnosis of Lymphoma and Multicentric Castleman Disease

Indiana University

NCT06580002 Phase 2

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

University of California, Irvi...

NCT07623850 Phase 1

A Phase I Study of JLM019 Injection

Jecho Biopharmaceuticals Co., ...

NCT06059391 Phase 2

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

City of Hope Medical Center

NCT05098613 Phase 1

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

University of Colorado, Denver

The Pathogenesis and Prognostic Factors of Lymphoma

Shanghai Zhongshan Hospital

NCT05998642 Phase 2

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Canadian Cancer Trials Group

NCT05794958 Phase 1

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Stanford University

Related Conditions

hodgkin lymphoma (8) acute lymphoblastic leukemia (3) chronic lymphocytic leukemia (3) leukemia (2) acute myeloid leukemia (2) myelodysplastic syndrome (2) follicular lymphoma (2) mantle cell lymphoma (2) large b cell lymphoma (2) lymphoma (2) cns lymphoma (2) high grade b cell lymphoma (2)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology